- |||||||||| tempol (MBM-02) / DMK Pharma, Matrix Biomed
Trial termination: Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. (clinicaltrials.gov) - Dec 6, 2022 P2/3, N=248, Terminated, Recruiting --> Terminated; Study did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo
- |||||||||| tempol (MBM-02) / DMK Pharma, Matrix Biomed
Enrollment open, Trial completion date, Trial primary completion date: Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. (clinicaltrials.gov) - Aug 26, 2021 P2/3, N=248, Recruiting, Recruiting --> Terminated; Study did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
- |||||||||| tempol (MBM-02) / DMK Pharma, Matrix Biomed
Trial initiation date: Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. (clinicaltrials.gov) - Aug 18, 2021 P2/3, N=248, Not yet recruiting, Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Jun 2022 Initiation date: May 2021 --> Aug 2021
|